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T
he mammalian innate immunesystemservesas a ﬁrst line of
defense and relies on the detection of speciﬁc microbial
ligands or “pathogen-associated molecular patterns” (PAMPs)
by pattern recognition molecules (PRMs), acting as microbial
sensors.
17 Inthiscontext, amongthemajorclassesofPRMsis
the NLR (NACHT and leucine rich repeat domain containing
proteins) family, which has emerged as a key player in innate
immunityresponses.TheNLRfamilycomprisesalargenumber
of proteins from both vertebrate and invertebrate animal
species, with >20 human proteins recognized.
815 It has been
shown that some NLR proteins detect bacterial cell wall
components such as lipopolysaccharides and/or peptidoglycan
(NOD1 or -2) as well as bacterial ﬂagellin (IPAF, NAIP).
1619
Indeed,NOD2 is a general bacterialsensor thatparticipatesinthe
innate immunity against Gram-positive bacteria (Streptococcus
pneumoniae and Listeria monocytogenes), Gram-negative bacteria
(Salmonella typhimurium), and mycobacteria (Mycobacterium
tuberculosis), while NOD1 recognizes primarily Gram-negative
bacteria (Escherichia coli, Chlamydia,a n dHelicobacter pylori).
NOD1 and 2 have also been involved in the induction of NF-k
B activation, caspase-1 activation, and apoptosis.
2022 Mutations
in NOD genes are also associated with a number of human
inﬂammatory diseases such as Crohn's disease (CD) and Blau
syndrome.
2328 Hence, NLR proteins present an interesting
avenue for the discovery and development of novel therapeutics
for autoimmune and inﬂammatory diseases.
29,30 Our eﬀorts
towardthediscoveryandoptimizationofa2-aminobenzimidazole
scaﬀold-based inhibitor that speciﬁcally inhibits NOD1 induced
NF-kB activation are described.
A library of ∼290,000 compounds from the NIH Molecular
Libraries Small Molecule Repository compound collection
(MLSMR)
31 was evaluated using a cell-based NF-kB driven





NOD2 and a 5-fold target-based selectivity over TNF-R (tumor
necrosis factor R)-mediated NF-kB activation. The compounds
satisfying the above-mentioned criteria were further subjected to
a series of counterscreen assays including an Alamar blue
cytotoxicityﬁlter(AID1849).
32Becausemultiplecellularstimuli,
acting through various pathways, can lead to NF-kB activation,
the TNF-R assay was designed to identify hits speciﬁc to TNF-R
modulated pathways (hence, non-NOD modulated). Secondary
assayswerealsoperformed toconﬁrmthat thesecompounds(a)
inhibit interleukin-8 (IL-8) secretion, which is a biologically
relevant downstream target of NOD1-stimulated signaling path-
way (AID2250), and (b) selectively inhibit NOD1-dependent
NF-kBactivationinothercelllines(AID2264).
32Ultimately,the
high-throughput screening (HTS) campaign resulted in the
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ABSTRACT: NOD1 (nucleotide-binding oligomerization domain 1) protein is a member of the
NLR (NACHT and leucine rich repeat domain containing proteins) protein family, which plays a
key role in innate immunity as a sensor of speciﬁc microbial components derived from bacterial
peptidoglycans and induction of inﬂammatory responses. Mutations in NOD proteins have been
associated with various inﬂammatory diseases that aﬀect NF-kB (nuclear factor kB) activity, a
major signaling pathway involved in apoptosis, inﬂammation, and immune response. A luciferase-
based reporter gene assay was utilized in a high-throughput screening program conducted under
the NIH-sponsored Molecular Libraries Probe Production Center Network program to identify
the active scaﬀolds. Herein, we report the chemical synthesis, structureactivity relationship
studies, downstream counterscreens, secondary assay data, and pharmacological proﬁling of the
2-aminobenzimidazole lead (compound 1c, ML130) as a potent and selective inhibitor of NOD1-induced NF-kB activation.
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identiﬁcation of three diﬀerent scaﬀolds, namely, tetrahydroiso-
quinoline (A), indoline (B), and benzimidazole (C) scaﬀolds
thatmettheinitialconﬁrmatoryscreeningcriteriaofinhibitionof
NOD1-mediated NF-kB activation with IC50 of e10 μM
(Figure 1). Of these three compound classes, only compounds
represented by scaﬀold C fulﬁlled the ﬁnal probe criteria of
activity (<1 μM) and selective inhibition of NOD1-induced
NF-kB activation. Details of the comprehensive screening plat-
form and pathway speciﬁc selectivity analysis are described in a
separate publication.
33
After conﬁrmation of the initial results, structureactivity
relationship (SAR) development was initiated for the indoline
scaﬀold using both an “analogue-by-catalog” approach and syn-
theticeﬀorts.Thisclassofcompoundswaspreparedviaacylation
of the starting indoline (2) with select acid chlorides in the
presence of pyridine (Table 1). Generation of the sulfonyl
chloride (4) was achieved by a sequential treatment of the
corresponding indoline derivative with chlorosulfuric acid in
the presence of phosphorus pentachloride.
34,35 The resulting
indoline sulfonyl chloride (4) was reacted with various substi-
tutedN-phenylpiperazines,underbasicconditions,tofurnishthe
ﬁnal products (1a27a, Table 1) in high yields (8595%).
The indoline scaﬀold was modiﬁed at three key positions
annotated as R1R3 (Table 1). In the ﬁrst set of compounds
(R1 = Me, 1a7a, 9a-16a, Table 1), analogues were synthesized
to test the eﬀect of the size of the aliphatic group at R2 (Me vs Et
vscyclopropyl)andthestereoelectronicinﬂuenceofthediﬀerent
groups at R3—electron-deﬁcient [Cl, NO2, C(O)Me, and CN]
vselectron-richorneutralgroups(OMeandMe).Subsequently,
similar analogues with R1 being H were prepared to study the
eﬀect of the indoline substitution. It was observed that
the bioactivity of these compounds (1a27a) is dependent on
the nature of the substituent R1. Compound 4a with R1 =M e
exhibited an IC50 = 1.87 ( 0.41 μM, but replacing the methyl
group in compound 4a with hydrogen (23a, Table 1) resulted in
complete loss of activity. A similar trend was observed with
another set of compounds (5a vs 18a, 7a vs 20a, and 12a vs 21a,
Table 1). The eﬀect of substituent R2 on the activity of these
compoundsdependsontheelectronicnatureofR3.Forexample,
if R3 = OMe (electron-donating group), the cyclopropyl ana-
logue (2a, Table 1) shows superior activity as compared to the
corresponding methyl analogue (15a, Table 1). On the other
hand, if R3 = C(O)Me (electron-withdrawing group), the
cyclopropyl analogue (7a, Table 1) is less active than the
corresponding methyl analogue (6a, Table 1). The nature of
substituent R3 also inﬂuenced the activity of these compounds.
Having R3 as an electron-withdrawing group such as NO2
(9a, Table 1) and C(O)Me (6a, Table 1) improved the activity
ofthesecompounds.ReplacingR3withneutralorelectron-donating
substituents decreases the NOD1 inhibitory activity (9a vs 14a
and 15a, Table 1). The data shown in Table 1 also indicate that
the compounds belonging to indoline scaﬀold are generally
Figure 1. Three scaﬀolds (IC50 e 10 μM) identiﬁed in the HTS
campaign.




b R1 R2 R3 n NOD1 NOD2 TNF-R
1a Me Me Cl 3 2.57( 0.40 1.75(0.07 5.76(1.50
2a Me cyclo-
propyl
OMe 2 0.51(0.15 0.39(0.01 3.85(1.50
3a Me cyclo-
propyl
H 2 >20 17.4( 1.83 15.3(0.46
4a Me Et NO2 3 1.87(0.41 1.55(0.28 4.92(1.52
5a Me cyclo-
propyl
Cl 3 5.6(1.12 3.63(0.58 7.26(1.6
6a Me Me COMe 3 4.42(0.48 3.72(0.21 6.0(0.91
7a Me cyclo-
propyl
COMe 5 10.26(3.51 7.90(1.6 >20
8a H Et Cl 2 >20 >20 >20
9a Me Me NO2 3 1.7(0.28 1.41(0.16 3.27(0.58
10a Me Et Cl 2 1.01(0.23 0.6(0.12 0.58(0.03
11a Me Et COMe 2 2.0(0.04 1.58(0.11 1.63(0.23
12a Me cyclo-
propyl
NO2 2 0.26(0.05 0.20(0.02 0.24(0.01
13a Me Me H 2 11.15(0.39 8.27(0.06 14.1(1.41
14a Me Me Me 2 5.76(0.57 3.45 (0.06 4.32(0.05
15a Me Me OMe 2 3.63(0.11 3.29(0.25 4.3(0.27
16a Me cyclo-
propyl
Me 2 >20 >20 >20
17a H Et CN 2 >20 >20 >20
18a H cyclo-
propyl
Cl 2 >20 >20 >20
19a H cyclo-
propyl
CN 2 >20 >20 >20
20a H cyclo-
propyl
COMe 2 >20 >20 >20
21a H cyclo-
propyl
NO2 2 6.5(0.27 8.45(0.14 >20
22a H Et COMe 2 >20 >20 >20
23a HE t N O 2 2 >20 >20 >20
24a H Me CN 2 5.87(0.14 9.24(0.23 8.79(0.55
25a H Me COMe 2 17.4(1.69 >20 >20
26a HM e N O 2 2 >20 >20 >20
27a H Me Cl 2 >20 >20 >20
aAll structures were inactive in an Alamar blue cytoxicity assay
(0% activity at 20 μM). (a) R2COCl, pyridine, room temperature, 12 h,
∼8090%. (b) ClSO3H, PCl5,0C, 7595%. (c) N-phenylpiperidine,
Et3N, room temperature, 6 h, 8595%.
bThe racemic mixture of
compounds (not the individual enantiomers) was subjected to the
biological assays.782 dx.doi.org/10.1021/ml200158b |ACS Med. Chem. Lett. 2011, 2, 780–785
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nonselectivetowardNOD1andNOD2andalsohaveaninhibitory
activityintheTNF-Rassay,whichsuggeststhattheseanaloguesact
via a nonselective mechanism. These observations, along with the
poor pH 7.4 buﬀer solubility of the series (∼0.1 μg/mL), guided
our decision to cease pursuit of this scaﬀold for probe generation.
The tetrahydroisoquinoline scaﬀold can be obtained via alkyla-
tion of the 4-bromomethyl benzoic acid 5 using various secondary
amines.
36The correspondingamine was isolated asahydrochloride
salt 6, which was coupled with various anilines using standard
coupling conditions (HBTU/DIPEA) to yield the ﬁnal products
1b27b (Scheme 1). It was observed that the bioactivity of
compounds belonging to tetrahydroisoquinoline series is highly
dependent on the nature of the substituent Y. Having Y as a
tetrahydroisoquinoline moiety (1b5b, Table 2) is pertinent for
the activity. Replacement of Y with other N-heterocycles such as
piperidine(6b,7b,10b,12b,an d15b,Table2) orindoline(8b,9b,
11b, 14b,a n d17b, Table 2) resulted in complete loss of activity.
Also, increasing the carbon chain length resulted in loss of activity
(4b vs 19b and 3b vs 20b, Table 2). Substituent “X” as the
C(O)NH group is imperative as reversal of the amide group
[replacement by NHC(O)] results in loss of the NOD1/2 and
TNF-R inhibitory activity (2b vs 26b and 4b vs 22b). Varying the
type of substituent Z shows that the electron-donating substituents
provided the more active compounds from the series (1b, 4b, 13b,
and 16b vs 5b, 21b, Table 2). The data shown in Table 2 also
indicate the nonselective nature of the tetrahydroisoquinoline
scaﬀold toward inhibition of NOD1- and NOD2-mediated NF-k
Bactivation.ThisseriesalsoexhibitinhibitoryactivityintheTNF-R
assay,whichindicatesthattheseanaloguesmayactviaanonselective
mechanism, similar to the indoline scaﬀold (Table 1).
The 2-aminobenzimidazole scaﬀold (C) was also explored for
optimization and SAR development (Table 3). Commercially
available 2-aminobenzimidazole 7 was treated with various
sulfonyl chlorides, in the presence of pyridine, to obtain the
corresponding sulfonamides.
37 The nature of substituent Y and
linkerXalsoinﬂuencedtheactivityofthe2-aminobenzimidazole
analogues (Table 3). The presence of substituent Y as the NH2
group on the benzimidazole ring is imperative as replacement
renders the compound inactive (68c, Table 3). For example,
theabsenceoftheNH2groupincompound6cdecreasesNOD1
inhibitory activity by 10-fold. Replacement of NH2 group with a
methyl(7c)orSHgroup(8c)resultsinlossofactivity(IC50>20
μM). Replacing the substitutions R1 and R2 with methyl groups
instead of hydrogen also jeopardizes the bioactivity (89c,
Table 3). Varying the type of substituent X shows that the
sulfonyl group provides the most active compound from the
series (1c vs 1015c, Table 3). Compound 10c with a methy-
lene linker or compound 13c with an ethoxy linker exhibited a
reduction in activity (15-fold) or loss of activity. Compound 11c
withacarbonyllinkerresultsinlossofselectivity,showingsimilar
activity in NOD1 (2.8 μM) and NOD2 (3.8 μM) assays. Also,
changing the linker to CH2CO (14c)o rCOCH2 (15c)
resulted in loss of activity. It was observed that the bioactivity of
1c and its analogues is highly dependent on the nature of the
substituent R3 (Table 3). The absence of the 4-substituent (4c)
or presence of other substituents such as 4-OMe (3c) or 4-NO2
(5c) reduces the compound potency by 420-fold.
In summary, compound 1c selectively (>36-fold) inhibits
NOD1-dependent activation of NF-kB as ascertained through
γ-tri-DAP-stimulated luciferase signaling in a NF-kB-linked
reporter assay (AID2333) in HEK293T cells containing en-
dogenous NOD1 levels with submicromolar potency (IC50 =
0.56 ( 0.04 μM), while not inhibiting either MDP-stimulated
(NOD2-dependent, AID2334) signaling in reporter cell lines
containing both endogenous and overexpressed NOD2 pro-
teins or TNF-R-induced NF-kB activation (AID2337)
(Table 3). Furthermore, compound 1c also shows selective
inhibitionofNOD1-(γ-tri-DAP)-dependentIL-8secretionbut
neither NOD2-dependent nor TNF-R-dependent IL-8 secre-
tion in biologically relevant MCF-7 cells (Figure 1 and Table 1
in the Supporting Information). Compound 1c also showed
selective NOD1-dependent inhibition of NF-kB activation via
NOD1(DAP,AID2264)modulationbutdidnotinhibitNF-kB
activation via PMA/ionomycin (AID2261) and doxorubicin
Scheme 1. Synthesis of the Tetrahydroisoquinoline Scaﬀold
and Its Analogues 1b26b
a
a(a) (i) Two equivalents of tetrahydroisoquinoline, THF, reﬂux, 12 h,
8085%; (ii) aqueous NaOH; (iii) 10% HCl. (b) Anilines, HBTU,
DIPEA, DMF, room temperature, 12 h, 5575%.
Table 2. SAR Analysis of the Tetrahydroisoquinoline Scaﬀold
a
aAll structures were inactive in an Alamar blue cytoxicity assay (0%
activity at 20 μM).783 dx.doi.org/10.1021/ml200158b |ACS Med. Chem. Lett. 2011, 2, 780–785
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(AID2255)-induced pathways (Figure 2 in the Supporting
Information).
In vitro ADME data for probe compound 1c indicate low
solubility and moderate to high “eﬀective” cell permeability at the
three pH levels tested (Table 4). Compound 1c also exhibits
moderate plasma protein binding with excellent stability in both
humanandmouseplasma.Itshowslowstabilityinthepresenceof
mouse microsomes but moderate stability in human microsomes
and exhibits LD50 >50 μM toward Fa2N-4 immortalized human
hepatocytes. Preliminary in vivo doseexposure data (using a
rapid assessment of compound exposure method, “RACE”)w e r e
also obtained for compound 1c in conjunction with quantitative
bioanalytical analysis to understand its pharmacokinetics in mice.
Mice dosed with compound 1c (30 and 15 mg/kg, ip) exhibited
signiﬁcant compound exposure at t = 20 min, which rapidly
decreased by t = 120 min. Mice dosed with compound 1c at
30mg/kg,ip,exhibitedahigherinitialcompoundexposurethanmice
dosedat15mg/kg,ip(5.5vs1.2μg/mL);however,plasmalevels
at t = 120 min were not improved (<0.5 μg/mL).
Compound 1c showed moderate activity (>50% inhibition)
when tested at a single concentration (10 μM) across PDSP
panel (NIMH Psychoactive Drug Screening Program) that
included 89% H1 (histamine), 92% 5HT6 (serotonin), and
69%5HT2Breceptors(seetheSupportingInformation,sectionD).
Compound 1c also exhibited excellent selectivity in Ambit
KinomeScreen showing little activity against 443 kinases at a
10 μMconcentration. Inhibitory activity (reportedas % control)
was observed only for the following kinases: AURK (Aurora
kinase)BandC(notA),21and23%,respectively;CFLT3(Fms-
like tyrosine kinase), 27% C; and RIOK2 (right open reading
frame), 6% C. Compound 1c was also found to be noncytotoxic
in NCI 60 human tumor cell line anticancer drug screen.
In summary, a new class of 2-aminobenzimidazoles has been
identiﬁedaspotentandselectiveinhibitorsofNOD1-inducedNF-
kB activation. Compound 1c has shown selective inhibition of
NOD1-induced NF-kB activation in HEK293 cells with no
cytotoxicity and was selected as a probe candidate molecule
(notated in PubChem as ML130).
38 Compound 1c was also
conﬁrmed in secondary assays by selectively inhibiting NOD1-
dependent IL-8 secretion and also selectively inhibiting the
NOD1-dependent pathway to NF-kB activation. Thus, ML130
andrelatedanaloguesprovidenewchemicaltoolsfordevelopment
Table 3. SAR Analysis of the 2-Amino Benzimidazole Scaﬀold
a
IC50 (μM)
entry R1 R2 R3 XY n NOD1 NOD2 TNF-R (NOD1-dependent)
1c H H Me SO2 NH2 6 0.56(0.04 >20 >20
2c H H Cl SO2 NH2 2 0.09(0.01 19.9 (0.15 >20
3c H H OMe SO2 NH2 4 2.7(0.69 >20 >20
4c HHH S O 2 NH2 4 2.2(0.21 >20 >20
5c HHN O 2 SO2 NH2 6 14.0(1.8 >20 >20
6c H H Me SO2 H 2 6.3(0.81 >20 >20
7c H H Me SO2 Me 2 >20 >20 >20
8c Me H Me SO2 SH 2 >20 >20 >20
9c Me Me Me SO2 NH2 4 >20 >20 >20
10c H H Cl CH2 NH2 2 7.7(0.82 11.9(0.5 >20
11c H H 2,4-diCl CO NH2 2 2.8+0.57 3.8(1.5 3.2
12c HHF C O N H 2 2 18.0(2.0 >20 >20
13c H H Cl (CH2)2CO NH2 2 16.3(3.7 >20 >20
14c H H OMe CH2CO NH2 2 >20 >20 >20
15c H H H COCH2 NH2 2 >20 >20 >20
aAll compounds were inactive in an Alamar blue cytoxicity assay (0% activity at 20 μM).















pH 5.0/6.2/7.4 pH 5.0/6.2/7.4 human 10 μM/1 μM mouse 10 μM/1 μM human/mouse human mouse
2/2/2 491/562/382 97.7/97.5 95.5/95.0 100/100 41.8 0.8
aCompound at 50 μM.
bPAMPA Pe: low, 5  10
6; moderate, 250  10
6; high, 1000  10
6.
cPlasma/PBS; compound at 1 μM, 3 h.
dPercent
remaining at 1 h.784 dx.doi.org/10.1021/ml200158b |ACS Med. Chem. Lett. 2011, 2, 780–785
ACS Medicinal Chemistry Letters LETTER
of pathway selective inhibitors of NF-kB activation. Further work
focused on improvement of potency and pharmacological proﬁle
of the probe molecule 1c is underway.
’ASSOCIATED CONTENT
b S Supporting Information. Synthetic procedures, charac-
terization of ﬁnal products, biological assay protocols and data,
andpharmacologyproﬁle.Thismaterialisavailablefreeofcharge
via the Internet at http://pubs.acs.org.
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